VerdoiaMBarbieriLKhediESuryapranataHDe LucaG. Percutaneous versus surgical revascularization for left main or multivessel coronary artery disease: results from a metaanalysis in era of DES. Angiology. 2018.
2.
AhnJMRohJHKimYH. Randomized trial of stents versus bypass surgery for left main coronary artery disease: 5-year outcomes of the precombat study. J Am Coll Cardiol. 2015;65(20):2198–206.
3.
MakikallioTHolmNRLindsayM. Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. Lancet. 2016;388(10061):2743–52.
4.
MohrFWMoriceMCKappeteinAP. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013;381(9867):629–38.
5.
FarkouhMEDomanskiMSleeperLA. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012;367(25):2375–84.
6.
ParkSJAhnJMKimYH. Trial of everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med. 2015;372(13):1204–12.
7.
StoneGWSabikJFSerruysPW. Everolimus-eluting stents or bypass surgery for left main coronary artery disease. N Engl J Med. 2016;375(23):2223–35.
8.
BoudriotEThieleHWaltherT. Randomized comparison of percutaneous coronary intervention with sirolimus-eluting stents versus coronary artery bypass grafting in unprotected left main stem stenosis. J Am Coll Cardiol. 2011;57(5):538–45.
9.
KamaleshMSharpTGTangXC. Percutaneous coronary intervention versus coronary bypass surgery in United States veterans with diabetes. J Am Coll Cardiol. 2013;61(8):808–16.
10.
ToutouzasKAnousakis-VlachochristouNTousoulisD. Everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med. 2015;373(6):580.
11.
GiliSD’AscenzoFDi SummaR. Radial versus femoral access for the treatment of left main lesion in the era of second-generation drug-eluting stents. Am J Cardiol. 2017;120(1):33–39.
12.
AminianAIglesiasJFVan MieghemC. First prospective multicenter experience with the 7 French Glidesheath slender for complex transradial coronary interventions. Catheter Cardiovasc Interv. 2017;89(6):1014–20.
13.
De BruyneBFearonWFPijlsNH. Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med. 2014;371(13):1208–17.
14.
BouchardDCarrierMDemersP. Statin in combination with beta-blocker therapy reduces postoperative stroke after coronary artery bypass graft surgery. Ann Thorac Surg. 2011;91(3):654–9.
15.
PasceriVPattiGNuscaAPristipinoCRichichiGDi SciascioG. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation. 2004;110(6):674–8.
16.
WindeckerSKolhPAlfonsoF. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35(37):2541–619.
17.
MontalescotGSechtemUAchenbachS. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the Management of Stable Coronary Artery Disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949–3003.
